 |
|
|
| |
Daclatasvir, an NS5A Replication Complex Inhibitor, Combined With Peginterferon Alfa-2a and
Ribavirin in Treatment-Naive HCV-Genotype 1 or 4 Patients: Phase 2b COMMAND-1 SVR12 Results
|
| |
| |
Reported by Jules Levin
AASLD Nov 9-13 2012 Boston
Hezode C,1 Hirschfield GM,2 Ghesquiere W,3 Sievert W,4 Rodriguez-Torres M,5 Shafran S,6 Thuluvath PJ,7 Tatum HA,8 Waked I,9 Esmat G,10 Lawitz EJ,11 Rustgi VK,12 Pol S,13 Weis N,14 Pockros P,15 Bourliere M,16 Serfaty L,17 Vierling JM,18 Fried MW,19 Weiland O,20 Brunetto MR,21 Everson GT,22 Zeuzem S,23 Kwo PY,24 Sulkowski M,25 Brau N,26 Wind-Rotolo M,27 Liu Z,28 Hughes EA,27 Yin PD,29 Schnittman S29
1Hôpital Henri Mondor, Universite Paris-Est, Creteil, France; 2Toronto Western Hospital, Toronto, Canada; 3Vancouver Island Health Authority, Victoria, Canada; 4Monash Medical Center, Melbourne, Australia; 5Fundación de Investigación, San Juan, Puerto Rico; 6University of Alberta Hospital, Edmonton, Canada; 7Mercy Medical Center, Baltimore, MD; 8Options Health Research, LLC, Tulsa, OK; 9National Liver Institute, Shebin Elkom, Egypt; 10The Faculty of Medicine Hepatology and Tropical Medicine, Cairo, Egypt; 11Alamo Medical Research, San Antonio, TX; 12Metropolitan Research, Fairfax, VA; 13Universite Paris Descartes, Inserm U1610 and Liver Unit, Hôpital Cochin, Paris, France; 14Copenhagen University Hospital, Hvidovre, Denmark; 15Scripps Clinic, La Jolla, CA; 16Hôpital Saint Joseph, Marseille, France; 17Hôpital Saint Antoine, Paris, France; 18Baylor College of Medicine, Houston, TX; 19University of North Carolina, Chapel Hill, NC; 20Karolinska University Hospital, Huddinge, Stockholm, Sweden; 21Azienda Ospedaliero Universitaria Pisana, Pisa, Italy; 22University of Colorado, Denver, CO; 23Goethe University, Frankfurt, Germany; 24Indiana University, Indianapolis, IN; 25Johns Hopkins University, Baltimore, MD; 26James J. Peters VAMC, Bronx, NY; 27Bristol-Myers Squibb Research and Development, Princeton NJ; 28Bristol-Myers Squibb Research and Development, Hopewell, NJ; 29Bristol-Myers Squibb Research and Development, Wallingford, CT
|
| |
|
|
|
|
|
